Last reviewed · How we verify
QLS-101
At a glance
| Generic name | QLS-101 |
|---|---|
| Also known as | QLS-101 ophthalmic solution |
| Sponsor | Qlaris Bio, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Safety and Tolerability of QLS-101 in NTG (PHASE2)
- A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 (PHASE2)
- Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP) (PHASE2)
- Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension). (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLS-101 CI brief — competitive landscape report
- QLS-101 updates RSS · CI watch RSS
- Qlaris Bio, Inc. portfolio CI